Click here to close now.




















Welcome!

News Feed Item

WuXi PharmaTech Announces Second-Quarter 2014 Results

SHANGHAI, Aug. 13, 2014 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading research and development services company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China and the United States, today announced its financial results for the second quarter of 2014. 

Second-Quarter 2014 Highlights

  • Net Revenues Increased 14.8% Year Over Year to $163.4 Million
  • Laboratory Services Net Revenues Grew 13.2% Year Over Year to $119.9 Million
  • China-Based Laboratory Services Net Revenues Increased 14.2% Year Over Year to $95.2 Million
  • U.S.-Based Laboratory Services Net Revenues Grew 9.6% Year Over Year to $24.7 Million
  • Manufacturing Services Net Revenues Increased 19.3% Year Over Year to $43.5 Million
  • GAAP Diluted Earnings Per ADS Remained Unchanged Year Over Year at $0.41
  • Non-GAAP Diluted Earnings Per ADS Increased 5.2% Year Over Year to $0.49
  • Full-Year 2014 Revenue and Diluted EPS Guidance Increased

Management Comment

"WuXi PharmaTech had another solid performance in the second quarter," said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech.  "We achieved record quarterly revenues, led by small-molecule manufacturing and biologics.  Our revenue growth was broad-based, with 19.3%, 14.2%, and 9.6% year-over-year growth in Manufacturing Services, China Lab Services, and U.S. Lab Services, respectively, and we exceeded our second-quarter guidance in revenues.

"We also had a good quarter in profitability, exceeding our second-quarter guidance for non-GAAP diluted EPS and achieving the top of our guidance range for GAAP diluted EPS," Dr. Li continued.  "Gross margin in the second quarter reflected year-over-year improvement of more than one full percentage point, driven by productivity initiatives, effective cost control, and the favorable impact of a depreciated RMB.  We are using our free cash flow to reinvest in our business as we build new capabilities in manufacturing, biologics, genomics, cell therapy, sales and marketing, information technology, and other areas.  We also purchased $66 million of our stock in the second quarter.

Our strong second-quarter performance gives us confidence about our performance for the remainder of the year.  We expect to sustain strong revenue growth in the second half of 2014, as we capitalize on the growing late-stage and commercial product pipeline in small-molecule manufacturing, the ramp-up of our biologics manufacturing business, and investments in new businesses.  We raise our full-year 2014 revenue guidance range from the previous $660-$670 million to $665-$670 million and increase our guidance for full-year 2014 GAAP and non-GAAP diluted EPS.

"We remain committed to building the premier open-access R&D platform that enables anyone and any company to discover and develop innovative medicines to benefit the world's patients," Dr. Li concluded.

Second-Quarter 2014 GAAP Results

Second-quarter 2014 net revenues increased 14.8% year over year to $163.4 million.  Revenue growth in Laboratory Services of 13.2% was driven by our comprehensive and integrated drug discovery and development services.  Revenue growth of 19.3% in Manufacturing Services was caused by strong demand in both research manufacturing and commercial manufacturing compared to the second quarter of 2013.

Second-quarter 2014 GAAP gross profit increased 18.9% year over year to $61.5 million due to 14.8% revenue growth and productivity improvement.  Gross margin increased year over year to 37.7% from 36.4% mainly due to improved productivity, the ramp-up of biologics services, and the favorable impact of a depreciated RMB versus the U.S. dollar, partially offset by increased labor costs in China.  Gross margin in Manufacturing Services increased year over year to 31.7% from 29.1%.  Gross margin in Laboratory Services increased year over year to 39.8% from 38.9%.

Second-quarter 2014 GAAP operating income increased 9.0% year over year to $28.0 million due to the 18.9% increase in gross profit, partially offset by increased general and administrative expenses, including hiring of senior management, and R&D expenses in biologics, discovery biology, genomics, and other areas.  Operating margin declined to 17.1% from 18.1% due to these increased general and administrative and R&D expenses, partially offset by the impact of a depreciated RMB versus the U.S. dollar, which is favorable because a large majority of our revenues are denominated in U.S. dollars and most of our expenses are denominated in RMB.

Second-quarter 2014 GAAP net income decreased 1.0% year over year to $29.3 million due to mark-to-market losses on foreign-exchange forward contracts of $2.5 million, compared to mark-to-market gains of $3.0 million in the second quarter of 2013, and a higher effective tax rate compared to the second quarter of 2013 due to the mix of taxable income and a $1.1 million one-time tax refund received in second-quarter 2013, partially offset by the 9.0% year-over-year increase in operating income, a $2.2 million gain on the sale of an investment by the corporate venture fund, smaller equity-method investment losses from our joint ventures with PRA and MedImmune and other equity-method investments, and higher interest income due to higher cash balances and higher interest rates.  Realized gains on settled foreign-exchange forward contracts were $1.6 million in the second quarter of 2014.

Second-quarter 2014 GAAP diluted earnings per ADS remained unchanged at $0.41 due to the 1.0% decrease in net income, offset by a lower number of outstanding ADSs as a result of share purchases.  Second-quarter 2014 GAAP comprehensive income decreased 35.4% year over year to $24.1 million due to the 1.0% decrease in GAAP net income and unfavorable currency translation adjustments, offset by unrealized gains on available-for-sale securities.

Second-Quarter 2014 Non-GAAP Results

Non-GAAP financial results exclude the impact of share-based compensation expenses and the amortization of acquired intangible assets and the associated deferred tax impact. 

Second-quarter 2014 non-GAAP gross profit increased 19.3% year over year to $63.2 million due to the 14.8% revenue growth and productivity improvement.  Non-GAAP gross margin increased year over year to 38.7% from 37.2% due to improved productivity, the ramp-up of biologics services, and the favorable impact of a depreciated RMB versus the U.S. dollar, offset by increased labor costs in China. 

Second-quarter 2014 non-GAAP operating income increased 13.8% year over year to $33.9 million due to the 19.3% increase in non-GAAP gross profit, partially offset by increased general and administrative expenses, including hiring of senior management, and R&D expenses in biologics, discovery biology, genomics, and other areas.  Non-GAAP operating margin decreased slightly to 20.8% from 20.9% due to increased general and administrative and R&D expenses, offset by the favorable impact of a depreciated RMB versus the U.S. dollar.

Second-quarter 2014 non-GAAP net income increased 4.5% year over year to $35.2 million due to the 13.8% year-over-year increase in non-GAAP operating income, a $2.2 million gain on the sale of an investment by the corporate venture fund, smaller equity-method investment losses from our joint ventures with PRA and MedImmune and other equity-method investments, and higher interest income due to higher cash balances and higher interest rates, partially offset by mark-to-market losses on foreign-exchange forward contracts of $2.5 million, compared to mark-to-market gains of $3.0 million in the second quarter of 2013, and a higher effective tax rate compared to the second quarter of 2013 due to the mix of taxable income and a $1.1 million one-time tax refund received in second-quarter 2013.  Realized gains on settled foreign-exchange forward contracts were $1.6 million in the second quarter of 2014.

Second-quarter 2014 non-GAAP diluted earnings per ADS increased 5.2% year over year to $0.49 due to the 4.5% increase in non-GAAP net income and a lower number of outstanding ADSs as a result of share purchases.  

Full-Year 2014 Financial Guidance

WuXi PharmaTech updates its full-year 2014 financial guidance:

  • Total net revenues of $665-$670 million, compared to previous guidance of $660-$670 million
  • GAAP diluted earnings per ADS of $1.55-$1.59, compared to previous guidance of $1.53-$1.58
  • Non-GAAP diluted earnings per ADS of $1.82-$1.86, compared to previous guidance of $1.80-$1.85
  • Capital expenditures of $95-$100 million, compared to previous guidance of about $85 million, driven primarily by capacity expansion in small-molecule manufacturing and investment in laboratories and technology in genomics, biologics, and biology

Third-Quarter 2014 Financial Guidance

WuXi PharmaTech provides the following third-quarter 2014 financial guidance:

  • Total net revenues of $171-$173 million
  • GAAP diluted earnings per ADS of $0.40-$0.42
  • Non-GAAP diluted earnings per ADS of $0.48-$0.50

 

WUXI PHARMATECH (CAYMAN) INC.

UNAUDITED CONSOLIDATED BALANCE SHEETS

(in thousands of U.S. dollars, except ordinary share, ADS and par value data)


June 30,

December 31,


2014

2013




Assets:



Current assets:



        Cash and cash equivalents

156,071

88,871

        Restricted cash

869

3,145

        Short-term investments

217,688

302,267

        Accounts receivable, net

134,311

126,996

        Amount due from related parties

2,374

1,168

        Inventories

41,518

45,097

        Prepaid expenses and other current assets

33,478

31,436

                    Total current assets

586,309

598,980

Non-current assets:



        Goodwill

31,084

31,087

        Property, plant and equipment, net

280,329

279,254

        Long-term investments

26,984

21,781

        Intangible assets, net

7,221

7,128

        Land use rights

5,442

5,604

        Deferred tax assets

249

251

        Other non-current assets

4,286

4,782

                    Total non-current assets

355,595

349,887

                    Total assets

941,904

948,867




Liabilities and equity:



Current liabilities:



        Short-term and current portion of long-term debt

115,642

67,853

        Accounts payable

36,900

33,477

        Amount due to related parties

256

218

        Accrued expenses

25,052

34,605

        Deferred revenue

25,201

28,149

        Advanced subsidies

13,237

13,958

        Other taxes payable

1,860

107

        Other current liabilities

19,678

15,738

                    Total current liabilities

237,826

194,105

Non-current liabilities:



        Long-term debt, excluding current portion

11,011

11,124

        Advanced subsidies

2,159

2,295

        Other non-current liabilities

6,924

6,594

                    Total non-current liabilities

20,094

20,013

                    Total liabilities

257,920

214,118




Equity:



       Ordinary shares ($0.02 par value, 5,002,550,000 authorized,  572,270,834  and 556,025,594 issued and outstanding as of December 31, 2013 and June 30, 2014, respectively) 

11,121

11,445

        Additional paid-in capital

266,808

353,173

        Retained earnings

350,328

303,171

        Accumulated other comprehensive income

55,727

66,960

Total shareholders' equity

683,984

734,749

                    Total liabilities and equity

941,904

948,867

 

WUXI PHARMATECH (CAYMAN) INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(In thousands of U.S. dollars, except ADS data and per ADS data)


Three Months Ended


Six Months Ended


 June 30,


June 30,




%




%


2014

2013

Change


2014

2013

Change









Net revenues:








      Laboratory Services

119,915

105,903

13.2%


225,467

203,384

10.9%

      Manufacturing Services

43,439

36,424

19.3%


84,604

70,808

19.5%

Total net revenues

163,354

142,327

14.8%


310,071

274,192

13.1%









Cost of revenues:








      Laboratory Services

(72,137)

(64,753)

11.4%


(136,486)

(125,629)

8.6%

      Manufacturing Services

(29,679)

(25,819)

15.0%


(58,420)

(49,402)

18.3%

Total cost of revenues

(101,816)

(90,572)

12.4%


(194,906)

(175,031)

11.4%









Gross profit:








      Laboratory Services

47,778

41,150

16.1%


88,981

77,755

14.4%

      Manufacturing Services

13,760

10,605

29.8%


26,184

21,406

22.3%

Total gross profit

61,538

51,755

18.9%


115,165

99,161

16.1%









Operating expenses:








      Selling and marketing expenses

(5,042)

(4,443)

13.5%


(9,542)

(8,374)

13.9%

      General and administrative expenses

(23,662)

(19,215)

23.1%


(45,000)

(37,421)

20.3%

      Research and development expenses

(4,831)

(2,405)

100.9%


(9,209)

(4,675)

97.0%

Total operating expenses

(33,535)

(26,063)

28.7%


(63,751)

(50,470)

26.3%

Operating income

28,003

25,692

9.0%


51,414

48,691

5.6%









Other income (expenses), net:








      Loss from equity-method investments

(810)

(1,401)

(42.2%)


(1,643)

(1,619)

1.5%

      Other income (expenses), net

4,620

7,203

(35.9%)


(820)

10,260

(108.0%)

      Interest income (expenses), net

4,198

1,997

110.2%


8,749

3,591

143.6%

Total other income (expenses), net

8,008

7,799

2.7%


6,286

12,232

(48.6%)









Income before income taxes

36,011

33,491

7.5%


57,700

60,923

(5.3%)

Income tax expense

(6,675)

(3,871)

72.4%


(10,542)

(9,591)

9.9%

Net income

29,336

29,620

(1.0%)


47,158

51,332

(8.1%)









Other comprehensive income:








Currency translation adjustments

(5,324)

7,733

(168.8%)


(11,158)

9,353

(219.3%)

Unrealized gains on available-for-sale securities

115

-

NA


(75)

-

NA

Comprehensive income

24,127

37,353

(35.4%)


35,925

60,685

(40.8%)









Basic net earnings per ADS

0.42

0.42

(0.6%)


0.66

0.73

(8.9%)

Diluted net earnings per ADS

0.41

0.41

(0.4%)


0.65

0.71

(8.9%)









Weighted average ADS outstanding—basic

70,671,831

70,892,623

(0.3%)


71,149,836

70,571,293

0.8%

Weighted average ADS outstanding—diluted

72,073,199

72,506,783

(0.6%)


72,735,360

72,151,600

0.8%

 

WUXI PHARMATECH (CAYMAN) INC.

RECONCILIATION OF GAAP TO NON-GAAP

(in thousands of U.S. dollars, except ADS data and per ADS data)










Three Months Ended


Six Months Ended


 June 30,


 June 30,


2014

2013

%
Change


2014

2013

%
Change

GAAP gross profit

61,538

51,755

18.9%


115,165

99,161

16.1%

GAAP gross margin

37.7%

36.4%



37.1%

36.2%


Adjustments:








        Share-based compensation

1,621

1,143

41.8%


2,687

2,182

23.1%

        Amortization of acquired intangible assets

48

65

(26.2%)


97

163

(40.5%)

Non-GAAP gross profit

63,207

52,963

19.3%


117,949

101,506

16.2%

Non-GAAP gross margin

38.7%

37.2%



38.0%

37.0%










GAAP operating income

28,003

25,692

9.0%


51,414

48,691

5.6%

GAAP operating margin

17.1%

18.1%



16.6%

17.8%


Adjustments:








        Share-based compensation

5,873

4,049

45.0%


10,286

7,649

34.5%

        Amortization of acquired intangible assets

48

65

(26.2%)


97

163

(40.5%)

Non-GAAP operating income

33,924

29,806

13.8%


61,797

56,503

9.4%

Non-GAAP operating margin

20.8%

20.9%



19.9%

20.6%










GAAP net income

29,336

29,620

(1.0%)


47,158

51,332

(8.1%)

GAAP net margin

18.0%

20.8%



15.2%

18.7%


Adjustments:








        Share-based compensation

5,873

4,049

45.0%


10,286

7,649

34.5%

        Amortization of acquired intangible assets

48

65

(26.2%)


97

163

(40.5%)

        Deferred tax impact related to acquired intangible assets

(16)

(21)

(23.8%)


(33)

(50)

(34.0%)

Non-GAAP net income

35,241

33,713

4.5%


57,508

59,094

(2.7%)

Non-GAAP net margin

21.6%

23.7%



18.5%

21.6%










Income attributable to holders of ADS (Non-GAAP):








Basic

35,241

33,713

4.5%


57,508

59,094

(2.7%)

Diluted

35,241

33,713

4.5%


57,508

59,094

(2.7%)









Basic earnings per ADS (Non-GAAP)

0.50

0.48

4.9%


0.81

0.84

(3.5%)

Diluted earnings per ADS (Non-GAAP)

0.49

0.46

5.2%


0.79

0.82

(3.5%)









Weighted average ADS outstanding








   – basic (Non-GAAP)

70,671,831

70,892,623

(0.3%)


71,149,836

70,571,293

0.8%

Weighted average ADS outstanding








  – diluted (Non-GAAP)

72,073,199

72,506,783

(0.6%)


72,735,360

72,151,600

0.8%

 

WUXI PHARMATECH (CAYMAN) INC.

REVENUE BREAKDOWN

(in thousands of U.S. dollars)










Three Months Ended


Six Months Ended


 June 30,


 June 30,










2014

2013

% Change


2014

2013

% Change

Net revenues:








        China-based Laboratory Services

95,243

83,399

14.2%


177,359

157,844

12.4%

        China-based Manufacturing Services

43,439

36,424

19.3%


84,604

70,808

19.5%

                    Subtotal

138,682

119,823

15.7%


261,963

228,652

14.6%

        U.S.-based Laboratory Services

24,672

22,504

9.6%


48,108

45,540

5.6%

Total net revenues

163,354

142,327

14.8%


310,071

274,192

13.1%

 

Conference Call

WuXi PharmaTech senior management will host a conference call at 8:00 am (U.S. Eastern) / 5:00 am (U.S. Pacific) / 8:00 pm (Beijing/Shanghai/Hong Kong) on August 14, 2014, to discuss its second-quarter 2014 financial results and future prospects.  The conference call may be accessed by calling:

China

4001 200 539

Hong Kong

800 905 927

Singapore

800 616 3222

United Kingdom

0800 015 9725

United States

1855 298 3404

United States—New York (toll)

+1 631 5142 526

Other countries (toll)

+65 6823 2299

Conference ID

7388753

A telephone replay will be available two hours after the call's completion at:

China

4001 842 240

Hong Kong

800 966 697

Singapore

800 616 2127

United Kingdom

0800 169 7301

United States

1866 846 0868

Conference ID

7388753

A live webcast of the conference call and replay will be available on the investor relations page of WuXi PharmaTech's website at http://www.wuxiapptec.com.

About WuXi PharmaTech

WuXi PharmaTech is a leading pharmaceutical, biotechnology, and medical device R&D outsourcing company, with operations in China and the United States.  As a research-driven and customer-focused company, WuXi PharmaTech provides a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process.  WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D.  WuXi PharmaTech's operating subsidiaries are known as WuXi AppTec.  For more information, please visit: http://www.wuxiapptec.com.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements are not historical facts, but instead are predictions about future events.  Examples of forward-looking statements in this press release include statements about our third-quarter and full-year 2014 guidance and our goal of building an open-access technology platform.  Although we believe that our predictions are reasonable, future events are inherently uncertain, and our forward-looking statements may turn out to be incorrect.  Our forward-looking statements are subject to risks relating to, among other things, our ability to control our costs and sustain revenue growth, to realize the anticipated benefits of our investments, to protect our clients' intellectual property, to compete effectively, and to complete the expansion of our manufacturing facilities in Changzhou.  Additional information about these and other relevant risks can be found in our Annual Report on Form 20-F for the year ended December 31, 2013.  The forward-looking statements in this press release speak only as of the date on which they are made, and we assume no obligation to update any forward-looking statements except as required by law.

Use of Non-GAAP Financial Measures 

We have provided the second-quarter and six-month 2013 and 2014 gross profit, gross margin, operating income, operating margin, net income, net margin, and diluted earnings per ADS, and estimated third-quarter and full-year 2014 diluted earnings per ADS on a non-GAAP basis, which excludes share-based compensation expenses and the amortization and deferred tax impact of acquired intangible assets.  The non-GAAP financial measures used in this press release are useful for understanding and assessing underlying business performance and operating trends, and we believe that management and investors benefit from referring to these non-GAAP financial measures in assessing our financial performance and liquidity and when planning and forecasting future periods.  We expect to continue to provide such non-GAAP financial measures on a quarterly basis using a consistent method.  You should not view non-GAAP results on a stand-alone basis or as a substitute for results under GAAP, or as being comparable to results reported or forecasted by other companies.

Statement Regarding Unaudited Financial Information

The financial information in this press release is unaudited and subject to adjustments. Adjustments to the financial statements may be identified when our annual financial statements are prepared and audit work is performed for the year-end audit, which could result in significant differences from this unaudited financial information.

For more information, please contact:

Ronald Aldridge (for investors)
Director of Investor Relations
Tel:   +1-201-585-2048
Email: [email protected]

Aaron Shi (for the media)
Associate Director of Corporate Communications
Tel:   +86-21-5046-4362
Email: [email protected]

SOURCE WuXi PharmaTech

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
It’s been proven time and time again that in tech, diversity drives greater innovation, better team productivity and greater profits and market share. So what can we do in our DevOps teams to embrace diversity and help transform the culture of development and operations into a true “DevOps” team? In her session at DevOps Summit, Stefana Muller, Director, Product Management – Continuous Delivery at CA Technologies, answered that question citing examples, showing how to create opportunities for ...
Puppet Labs has announced the next major update to its flagship product: Puppet Enterprise 2015.2. This release includes new features providing DevOps teams with clarity, simplicity and additional management capabilities, including an all-new user interface, an interactive graph for visualizing infrastructure code, a new unified agent and broader infrastructure support.
SYS-CON Events announced today that Pythian, a global IT services company specializing in helping companies leverage disruptive technologies to optimize revenue-generating systems, has been named “Bronze Sponsor” of SYS-CON's 17th Cloud Expo, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. Founded in 1997, Pythian is a global IT services company that helps companies compete by adopting disruptive technologies such as cloud, Big Data, advance...
Skeuomorphism usually means retaining existing design cues in something new that doesn’t actually need them. However, the concept of skeuomorphism can be thought of as relating more broadly to applying existing patterns to new technologies that, in fact, cry out for new approaches. In his session at DevOps Summit, Gordon Haff, Senior Cloud Strategy Marketing and Evangelism Manager at Red Hat, discussed why containers should be paired with new architectural practices such as microservices rathe...
IBM’s Blue Box Cloud, powered by OpenStack, is now available in any of IBM’s globally integrated cloud data centers running SoftLayer infrastructure. Less than 90 days after its acquisition of Blue Box, IBM has integrated its Blue Box Cloud Dedicated private-cloud-as-a-service into its broader portfolio of OpenStack® based solutions. The announcement, made today at the OpenStack Silicon Valley event, further highlights IBM’s continued support to deliver OpenStack solutions across all cloud depl...
ElasticBox, the agile application delivery manager, announced freely available public boxes for the DevOps community. ElasticBox works with enterprises to help them deploy any application to any cloud. Public boxes are curated reference boxes that represent some of the most popular applications and tools for orchestrating deployments at scale. Boxes are an adaptive way to represent reusable infrastructure as components of code. Boxes contain scripts, variables, and metadata to automate proces...
Puppet Labs is pleased to share the findings from our 2015 State of DevOps Survey. We have deepened our understanding of how DevOps enables IT performance and organizational performance, based on responses from more than 20,000 technical professionals we’ve surveyed over the past four years. The 2015 State of DevOps Report reveals high-performing IT organizations deploy 30x more frequently with 200x shorter lead times. They have 60x fewer failures and recover 168x faster
To support developers and operations professionals in their push to implement DevOps principles for their infrastructure environments, ProfitBricks, a provider of cloud infrastructure, is adding support for DevOps tools Ansible and Chef. Ansible is a platform for configuring and managing data center infrastructure that combines multi-node software deployment, ad hoc task execution, and configuration management, and is used by DevOps professionals as they use its playbooks functionality to autom...
SYS-CON Events announced today that IceWarp will exhibit at the 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. IceWarp, the leader of cloud and on-premise messaging, delivers secured email, chat, documents, conferencing and collaboration to today's mobile workforce, all in one unified interface
Containers are not new, but renewed commitments to performance, flexibility, and agility have propelled them to the top of the agenda today. By working without the need for virtualization and its overhead, containers are seen as the perfect way to deploy apps and services across multiple clouds. Containers can handle anything from file types to operating systems and services, including microservices. What are microservices? Unlike what the name implies, microservices are not necessarily small,...
All major researchers estimate there will be tens of billions devices - computers, smartphones, tablets, and sensors - connected to the Internet by 2020. This number will continue to grow at a rapid pace for the next several decades. With major technology companies and startups seriously embracing IoT strategies, now is the perfect time to attend @ThingsExpo, November 3-5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. Learn what is going on, contribute to the discussions, and e...
This Enterprise Strategy Group lab validation report of the NEC Express5800/R320 server with Intel® Xeon® processor presents the benefits of 99.999% uptime NEC fault-tolerant servers that lower overall virtualized server total cost of ownership. This report also includes survey data on the significant costs associated with system outages impacting enterprise and web applications. Click Here to Download Report Now!
SYS-CON Events announced today that G2G3 will exhibit at SYS-CON's @DevOpsSummit Silicon Valley, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. Based on a collective appreciation for user experience, design, and technology, G2G3 is uniquely qualified and motivated to redefine how organizations and people engage in an increasingly digital world.
Too often with compelling new technologies market participants become overly enamored with that attractiveness of the technology and neglect underlying business drivers. This tendency, what some call the “newest shiny object syndrome,” is understandable given that virtually all of us are heavily engaged in technology. But it is also mistaken. Without concrete business cases driving its deployment, IoT, like many other technologies before it, will fade into obscurity.
Whether you like it or not, DevOps is on track for a remarkable alliance with security. The SEC didn’t approve the merger. And your boss hasn’t heard anything about it. Yet, this unruly triumvirate will soon dominate and deliver DevSecOps faster, cheaper, better, and on an unprecedented scale. In his session at DevOps Summit, Frank Bunger, VP of Customer Success at ScriptRock, will discuss how this cathartic moment will propel the DevOps movement from such stuff as dreams are made on to a prac...